Ali Aldaoud Selected Research

Drug Therapy (Chemotherapy)

1/2021	Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
1/2020	Allogeneic Hematopoietic Stem Cell Transplantation in a Rare Case of Tonsillar Mast Cell Sarcoma.
7/2007	High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
12/2005	Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
3/2005	Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ali Aldaoud Research Topics

Disease

3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 07/2007 - 03/2005
2	Multiple Myeloma 02/2022 - 01/2018
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 01/2019
2	Infections 10/2017 - 09/2009
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2005 - 03/2005
1	Mast-Cell Leukemia (Leukemia, Mast Cell) 01/2020
1	Mast-Cell Sarcoma 01/2020
1	Leukoencephalopathies 10/2017
1	Residual Neoplasm 10/2017
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 10/2017
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 09/2009
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2008
1	Lymphoma (Lymphomas) 07/2007
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2005

Drug/Important Bio-Agent (IBA)

3	Rituximab (Mabthera)FDA Link 07/2007 - 03/2005
2	Dexamethasone (Maxidex)FDA LinkGeneric 02/2022 - 01/2018
2	Lenalidomide (CC 5013)FDA Link 01/2018 - 10/2017
2	Bendamustine Hydrochloride FDA Link 09/2009 - 07/2007
2	Vincristine (Oncovin)FDA LinkGeneric 12/2005 - 03/2005
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2005 - 03/2005
2	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2005 - 03/2005
2	Prednisone (Sone)FDA LinkGeneric 12/2005 - 03/2005
1	Immunologic Factors (Immunomodulators)IBA 02/2022
1	Bortezomib (Velcade)FDA Link 02/2022
1	pomalidomideIBA 02/2022
1	paragonIBA 01/2021
1	130-nm albumin-bound paclitaxelIBA 01/2021
1	Gemcitabine FDA Link 01/2021
1	Pharmaceutical PreparationsIBA 01/2018
1	Genetic Markers (Genetic Marker)IBA 10/2017
1	Chlorambucil (Leukeran)FDA Link 09/2009
1	Bexarotene (LGD1069)FDA Link 01/2008
1	Mitoxantrone (Novantrone)FDA LinkGeneric 07/2007
1	Monoclonal AntibodiesIBA 12/2005

Therapy/Procedure

5	Drug Therapy (Chemotherapy) 01/2021 - 03/2005
4	Therapeutics 01/2019 - 03/2005
1	Hematopoietic Stem Cell Transplantation 01/2020
1	Immunotherapy 07/2007
1	Stem Cell Transplantation 04/2005
1	Chemoradiotherapy 04/2005
1	Time-to-Treatment 03/2005